Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxalta Inc.

Division of Shire PLC
www.baxalta.com

Latest From Baxalta Inc.

Shire Will Cut Manufacturing Sites As It Looks For More Baxalta Synergies

Shire had a combined 17 manufacturing plants after the Baxalta merger, but plans to cut that to a total of 12. Manufacturing issues hit sales of its HAE drug Cinryze in the third quarter, and the firm is losing Lialda sales faster than expected.

Manufacturing Sales & Earnings

ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.

BioPharmaceutical Deals

Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership

Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.

Business Strategies Deals

Shire May Spin Out Neuroscience Unit To Tighten Rare Disease Focus

The merger with Baxalta left Shire a portfolio consisting of 80% rare disease therapies, suggesting logically that the company might want to exit the primary care ADHD space.

Business Strategies Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Baxter BioScience
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Shire PLC
  • Senior Management
  • Ludwig N Hantson, PhD, Pres. & CEO
    Robert J Hombach, EVP, CF & COO
    John J Orloff, MD, EVP, Head, R&D & CSO
  • Contact Info
  • Baxalta Inc.
    Phone: (224) 940-2000
    One Baxter Pkwy.
    Deerfield, IL 60015
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register